Table 1.
Glasdegib dose | |||||||
---|---|---|---|---|---|---|---|
25 mg n = 3 | 50 mg n = 4 | 100 mg n = 6 | Total | ||||
Male | Female | Male | Female | Male | Female | ||
Number of patients | 2 | 1 | 3 | 1 | 3 | 3 | 13 |
Age, years | |||||||
Median | 64.5 | 49.0 | 68.0 | 65.0 | 73.0 | 68.0 | 68.0 |
Range | 63–66 | 49–49 | 64–72 | 65–65 | 71–81 | 55–72 | 49–81 |
ECOG PS, n (%) | |||||||
0 | 1 (33) | 2 (50) | 4 (67) | 7 (54) | |||
1 | 2 (67) | 2 (50) | 1 (17) | 5 (38) | |||
2 | 0 | 0 | 1 (17) | 1 (8) | |||
Primary diagnosis, n (%) | |||||||
MDS | 2 (67) | 1 (25) | 1 (17) | 4 (31) | |||
MF | 0 | 0 | 1 (17) | 1 (8) | |||
CMML | 0 | 1 (25) | 0 | 1 (8) | |||
AML | 1 (33) | 2 (50) | 4 (67) | 7 (54) | |||
Prior regimens, n (%) | |||||||
1 | 1 (33) | 2 (50) | 3 (50) | 6 (46) | |||
2 | 1(33) | 0 | 1 (17) | 2 (15) | |||
3 | 0 | 1 (25) | 0 | 1 (8) | |||
>3 | 1 (33) | 1 (25) | 2 (33) | 4 (31) |
AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance score; MDS, myelodysplastic syndrome; MF, myelofibrosis.